Needham & Company LLC Reaffirms “Buy” Rating for Artivion (NYSE:AORT)

Artivion (NYSE:AORT)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. They currently have a $34.00 price objective on the stock. Needham & Company LLC’s price target indicates a potential upside of 10.55% from the stock’s previous close.

Several other analysts have also weighed in on the stock. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Oppenheimer raised their target price on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $31.80.

Artivion Trading Up 0.4 %

Shares of AORT traded up $0.12 during trading hours on Tuesday, hitting $30.76. 46,311 shares of the stock were exchanged, compared to its average volume of 351,062. Artivion has a fifty-two week low of $16.48 and a fifty-two week high of $32.33. The business has a 50-day moving average of $29.15 and a 200-day moving average of $27.33. The firm has a market capitalization of $1.29 billion, a P/E ratio of -1,540.75 and a beta of 1.74. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Insider Buying and Selling

In other news, VP Andrew M. Green sold 7,618 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the transaction, the vice president now directly owns 33,503 shares in the company, valued at approximately $1,005,090. This represents a 18.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jean F. Holloway sold 8,070 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the transaction, the senior vice president now directly owns 153,862 shares in the company, valued at approximately $4,634,323.44. This represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,017 shares of company stock worth $600,007 in the last quarter. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP grew its position in shares of Artivion by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock worth $44,090,000 after buying an additional 46,267 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after buying an additional 125,668 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of Artivion in the third quarter worth about $5,798,000. Tidal Investments LLC boosted its position in shares of Artivion by 602.2% during the 3rd quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after acquiring an additional 134,642 shares during the last quarter. Finally, Sio Capital Management LLC bought a new stake in Artivion in the third quarter worth $3,226,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.